Clinical meaning
Mixed connective tissue disease (MCTD) is an overlap autoimmune syndrome first described by Sharp in 1972, defined by the presence of high-titer anti-U1 ribonucleoprotein (anti-U1 RNP) antibodies in conjunction with clinical features spanning at least two of the following: systemic lupus erythematosus (SLE), systemic sclerosis (SSc), polymyositis (PM), and rheumatoid arthritis (RA). The U1 RNP complex is a nuclear ribonucleoprotein involved in pre-mRNA splicing; autoantibodies against its 70-kDa, A, and C protein subunits drive immune complex formation, complement activation via the classical pathway, and T-cell-mediated tissue injury across multiple organ systems. The pathogenesis involves loss of immune tolerance to the U1 snRNP complex, leading to autoreactive CD4+ T-helper cells that provide help to autoreactive B cells, amplifying autoantibody production. Immune complexes deposit in small and medium-sized blood vessels, triggering endothelial injury and vasculopathy that accounts for the hallmark feature of Raynaud phenomenon. The initial clinical presentation typically includes Raynaud phenomenon with puffy, swollen fingers (sausage digits) that may progress to sclerodactyly as the scleroderma component evolves. Vascular endothelial injury and intimal proliferation in the pulmonary vasculature leads to pulmonary arterial hypertension (PAH), the leading cause of mortality in MCTD, occurring in 10-45% of patients. Inflammatory myopathy manifests as proximal muscle weakness with elevated creatine kinase (CK) from immune-mediated muscle fiber destruction. Esophageal dysmotility affects up to 85% of patients due to smooth muscle fibrosis and atrophy in the lower two-thirds of the esophagus, identical to the mechanism seen in systemic sclerosis. Polyarthritis reflects the RA-like component, with symmetric joint inflammation driven by synovial pannus formation. Interstitial lung disease can develop from alveolar epithelial injury and fibroblast activation. Unlike SLE, severe renal disease is less common in MCTD but carries a poor prognosis when present, typically manifesting as membranous nephropathy. MCTD features may evolve over years, and patients may initially present with undifferentiated features that only later meet full overlap criteria.